Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,210
  • Shares Outstanding, K 12,886
  • Annual Sales, $ 230 K
  • Annual Income, $ -6,660 K
  • 60-Month Beta 0.99
  • Price/Sales 164.78
  • Price/Cash Flow N/A
  • Price/Book 5.19
Trade LEXX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 08/31/24
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.13
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +11.60%
on 06/26/24
3.63 -23.14%
on 06/13/24
-0.45 (-13.89%)
since 06/12/24
3-Month
1.85 +50.81%
on 04/16/24
4.44 -37.16%
on 06/03/24
+0.67 (+31.60%)
since 04/12/24
52-Week
0.72 +287.50%
on 07/17/23
6.85 -59.27%
on 03/11/24
+1.94 (+228.24%)
since 07/12/23

Most Recent Stories

More News
Lexaria Bioscience (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that human pilot study #2, GLP-1-H24-2, has now completed all dosing. The final DehydraTECH study...

LEXX : 2.79 (-0.71%)
Lexaria Bioscience (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced three new patent awards. In the European Union, the company received a new patent in Lexaria’s...

LEXX : 2.79 (-0.71%)
LEXXW : 1.0100 (-3.81%)
Lexaria Bioscience (NASDAQ: LEXX) Eyeing Strategic Partnering with Leading GLP-1 Players

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is doubling down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. “The company is optimistic...

LEXXW : 1.0100 (-3.81%)
LEXX : 2.79 (-0.71%)
Lexaria Bioscience (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2, GLP-1-H24-2. The study...

LEXX : 2.79 (-0.71%)
Lexaria Bioscience (NASDAQ: LEXX) Engages CRO for DehydraTECH GLP-1 Human Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to oversee execution of the company’s...

LEXX : 2.79 (-0.71%)
LEXXW : 1.0100 (-3.81%)
Lexaria Bioscience (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the hiring of a Contract Research Organization (“CRO”) for its third human pilot study. This marks a...

LEXX : 2.79 (-0.71%)
Lexaria Bioscience (NASDAQ: LEXX) Grows Portfolio to 43 Granted Patents Worldwide

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, started 2024 with a portfolio of 38 patents granted worldwide, having received ten new granted patents during 2023, the...

LEXX : 2.79 (-0.71%)
Lexaria (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting that the second round of dosing for all nine study participants in the second arm of its human pilot...

LEXX : 2.79 (-0.71%)
Lexaria Bioscience (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 ( https://cnw.fm/g0mZl...

LEXX : 2.79 (-0.71%)
Lexaria Bioscience (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is partnering with a contract research organization (“CRO”) to conduct its human pilot study #3. According to...

LEXX : 2.79 (-0.71%)
LEXXW : 1.0100 (-3.81%)
LLY : 948.40 (+1.53%)

Business Summary

Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules....

See More

Key Turning Points

3rd Resistance Point 3.06
2nd Resistance Point 2.98
1st Resistance Point 2.88
Last Price 2.79
1st Support Level 2.70
2nd Support Level 2.62
3rd Support Level 2.52

See More

52-Week High 6.85
Fibonacci 61.8% 4.51
Fibonacci 50% 3.78
Fibonacci 38.2% 3.06
Last Price 2.79
52-Week Low 0.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar